News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
692,563 Results
Type
Article (39411)
Company Profile (247)
Press Release (652905)
Section
Business (204044)
Career Advice (2005)
Deals (35412)
Drug Delivery (93)
Drug Development (80951)
Employer Resources (169)
FDA (16136)
Job Trends (14828)
News (344905)
Policy (32480)
Tag
Academia (2535)
Alliances (49323)
Alzheimer's disease (1314)
Approvals (16120)
Artificial intelligence (199)
Bankruptcy (357)
Best Places to Work (11637)
Biotechnology (175)
Breast cancer (225)
Cancer (1712)
Cardiovascular disease (128)
Career advice (1669)
CAR-T (121)
Cell therapy (353)
Clinical research (65252)
Collaboration (659)
Compensation (370)
COVID-19 (2564)
C-suite (160)
Data (1629)
Diabetes (211)
Diagnostics (6282)
Earnings (85441)
Employer resources (146)
Events (110866)
Executive appointments (564)
FDA (17037)
Funding (602)
Gene therapy (245)
GLP-1 (649)
Government (4357)
Healthcare (18768)
Infectious disease (2675)
Interviews (310)
IPO (16460)
Job creations (3627)
Job search strategy (1420)
Layoffs (437)
Legal (7888)
Lung cancer (255)
Manufacturing (235)
Medical device (13261)
Medtech (13266)
Mergers & acquisitions (19326)
Metabolic disorders (548)
Neuroscience (1715)
NextGen: Class of 2025 (6509)
Non-profit (4475)
Northern California (2090)
Obesity (306)
Opinion (194)
Patents (164)
People (56829)
Phase I (20317)
Phase II (28747)
Phase III (21403)
Pipeline (712)
Postmarket research (2562)
Preclinical (8575)
Radiopharmaceuticals (241)
Rare diseases (321)
Real estate (5897)
Regulatory (21921)
Research institute (2311)
Resumes & cover letters (349)
Southern California (1791)
Startups (3567)
United States (18436)
Vaccines (611)
Weight loss (208)
Date
Today (92)
Last 7 days (593)
Last 30 days (2613)
Last 365 days (34452)
2025 (4428)
2024 (35229)
2023 (40093)
2022 (51178)
2021 (55710)
2020 (54083)
2019 (46538)
2018 (35018)
2017 (32109)
2016 (31480)
2015 (37552)
2014 (31318)
2013 (26345)
2012 (28570)
2011 (29263)
2010 (27328)
Location
Africa (716)
Arizona (211)
Asia (37508)
Australia (6132)
California (4761)
Canada (1715)
China (393)
Colorado (217)
Connecticut (230)
Europe (80387)
Florida (688)
Georgia (165)
Illinois (455)
Indiana (259)
Japan (121)
Maryland (739)
Massachusetts (3602)
Michigan (198)
Minnesota (334)
New Jersey (1347)
New York (1359)
North Carolina (833)
Northern California (2090)
Ohio (173)
Pennsylvania (1098)
South America (1093)
Southern California (1791)
Texas (701)
Utah (143)
Washington State (467)
692,563 Results for "seagen inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Policy
Arbitration Dispute Between Daiichi Sankyo and Seagen Ends
A dispute between Daiichi Sankyo Co., Ltd. (TSE: 4568) and Seagen Inc. is now concluded and Seagen has paid Daiichi Sankyo approximately U.S. $47 million in connection with attorneys’ fees and costs plus interest awarded by the arbitrator of the party’s dispute.
June 28, 2024
·
1 min read
Patents
Daiichi Sankyo Wins $47M in ADC Patent Arbitration With Seagen, Pfizer Dispute Looms
Daiichi Sankyo has secured a victory in its patent arbitration with Seagen, nabbing a $47 million award for attorneys’ fees and other costs, plus interest. However, a larger patent battle with Pfizer remains.
July 1, 2024
·
2 min read
·
Tristan Manalac
Policy
Daiichi Sankyo Wins $47M in ADC Patent Arbitration With Seagen, Pfizer Dispute Looms
Daiichi Sankyo has secured a victory in its patent arbitration with Seagen, nabbing a $47 million award for attorneys’ fees and other costs, plus interest. However, a larger patent battle with Pfizer remains.
July 1, 2024
·
2 min read
·
Tristan Manalac
Deals
Pfizer Completes Acquisition of Seagen
Pfizer Inc. (NYSE: PFE) today announced the successful completion of its acquisition of Seagen Inc. (NASDAQ: SGEN), a global biotechnology company that discovers, develops and commercializes transformative cancer medicines.
December 14, 2023
·
8 min read
Drug Development
Pfizer’s $43B Seagen Buy Starts to Pay Off with Adcetris Phase III Data in DLBCL
Antibody-drug conjugate Adcetris, when used with rituximab or lenalidomide, improved overall survival in patients with relapsed or refractory diffuse large B-cell lymphoma. Pfizer secured access to Seagen’s ADC in March 2023.
March 12, 2024
·
2 min read
·
Tristan Manalac
Deals
Pfizer Receives All Required Regulatory Approvals to Complete the Acquisition of Seagen
Pfizer Inc. (NYSE: PFE) today announces that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, expired December 11, 2023, with respect to Pfizer’s pending acquisition of Seagen Inc.
December 12, 2023
·
9 min read
Business
Seagen Third Quarter 2023 Financial Results Reflect Strong Product Sales Growth, and Significant Portfolio and Pipeline Progress
Seagen Inc. (Nasdaq:SGEN) (Seagen or the Company) reported financial results today for the third quarter ended September 30, 2023.
November 1, 2023
·
20 min read
Business
Seagen to Report Third Quarter 2023 Financial Results on November 1, 2023
Seagen Inc. (Nasdaq: SGEN) announced today that it will report third quarter 2023 financial results on Wednesday, November 1, 2023.
October 12, 2023
·
1 min read
Policy
USPTO Rules Against Seagen in ADC Patent Battle with Daiichi Sankyo
The U.S. Patent and Trademark Office has sided with Daiichi over Seagen in a years-long patent saga concerning a key linker technology used in its blockbuster Enhertu antibody-drug conjugate for cancer.
January 17, 2024
·
2 min read
·
Tristan Manalac
Deals
Seagen Stockholders Approve Acquisition by Pfizer
Following a special meeting of its stockholders, Seagen Inc. (Nasdaq: SGEN) today announced that its stockholders voted to approve a proposal to adopt the previously announced merger agreement under which Pfizer will acquire Seagen for $229 per share in cash.
May 30, 2023
·
4 min read
1 of 69,257
Next
